tiprankstipranks
Oramed downgraded to Hold at Canaccord after ORMD-0801 discontinued
The Fly

Oramed downgraded to Hold at Canaccord after ORMD-0801 discontinued

Canaccord analyst Edward Nash downgraded Oramed to Hold from Buy with a price target of $3, down from $30, after the company announced its Phase 3 ORA-D-013-1 study of ORMD-0801 did not meet the primary endpoint and also missed the key secondary endpoint. As a result, the company discontinued the oral insulin program in T2D and Nash sees "no further value in the clinical pipeline as it stands," noting that his $3 price target is based on the current cash per share value.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ORMP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles